{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T17:01:52Z","timestamp":1784480512062,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,19]]},"DOI":"10.7759\/cureus.112958","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T16:04:22Z","timestamp":1784477062000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Effectiveness and Challenges in a Moroccan Tertiary Care Center"],"prefix":"10.7759","author":[{"given":"Fatimaezzahra","family":"Lairani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane","family":"Rizkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Aouroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama","family":"Nacir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Ait Errami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Oubaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zouhour","family":"Samlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadija","family":"Krati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres J","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017, 389:1741-55. 10.1016\/S0140-6736(16)31711-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro R","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017, 389:1756-70. 10.1016\/S0140-6736(16)32126-2","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner D","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al.. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021, 160:1570-83. 10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres J","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, et al.. ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020, 14:4-22. 10.1093\/ecco-jcc\/jjz180","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine T","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al.. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022, 16:2-17. 10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein JD","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP. AGA Clinical Practice Guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease. Gastroenterology. 2021, 160:2496-508. 10.1053\/j.gastro.2021.04.022","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert JP","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009, 104:760-7. 10.1038\/ajg.2008.88","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin S","year":"2011","unstructured":"Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011, 33:987-95. 10.1111\/j.1365-2036.2011.04612.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.05.005","article-title":"The use of biologic agents in pregnancy and breastfeeding","volume":"43","author":"Horst S","year":"2014","unstructured":"Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am. 2014, 43:495-508. 10.1016\/j.gtc.2014.05.005","journal-title":"Gastroenterol Clin North Am"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy NA","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, et al.. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019, 4:341-53. 10.1016\/S2468-1253(19)30012-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan GG","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015, 12:720-7. 10.1038\/nrgastro.2015.150","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present DH","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al.. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999, 340:1398-405. 10.1056\/NEJM199905063401804","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda G","year":"2016","unstructured":"Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016, 7:e135. 10.1038\/ctg.2015.63","journal-title":"Clin Transl Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001396","article-title":"A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease","volume":"116","author":"Cheifetz AS","year":"2021","unstructured":"Cheifetz AS, Abreu MT, Afif W, et al.. A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease. Am J Gastroenterol. 2021, 116:2014-25. 10.14309\/ajg.0000000000001396","journal-title":"Am J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306709","article-title":"A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease","volume":"63","author":"Gecse KB","year":"2014","unstructured":"Gecse KB, Bemelman W, Kamm MA, et al.. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014, 63:1381-92. 10.1136\/gutjnl-2013-306709","journal-title":"Gut"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144157","article-title":"Predictors of anti-TNF therapy failure among inflammatory bowel disease patients in Saudi Arabia: a single-center study","volume":"11","author":"Alharbi O","year":"2022","unstructured":"Alharbi O, Aljebreen AM, Azzam NA, et al.. Predictors of anti-TNF therapy failure among inflammatory bowel disease patients in Saudi Arabia: a single-center study. J Clin Med. 2022, 11:10.3390\/jcm11144157","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa123","article-title":"Are quality metrics in inflammatory bowel disease rooted on substantial quality evidence? A systematic review","volume":"15","author":"Weissman S","year":"2021","unstructured":"Weissman S, Goldowsky A, Mehta TI, Sciarra MA, Feuerstein JD. Are quality metrics in inflammatory bowel disease rooted on substantial quality evidence? A systematic review. J Crohns Colitis. 2021, 15:10.1093\/ecco-jcc\/jjaa123","journal-title":"J Crohns Colitis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael K","year":"2019","unstructured":"Papamichael K, Cheifetz AS, Melmed GY, et al.. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019, 17:1655-68.e3. 10.1016\/j.cgh.2019.03.037","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507452-anti-tumor-necrosis-factor-therapy-in-inflammatory-bowel-disease-effectiveness-and-challenges-in-a-moroccan-tertiary-care-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T16:04:23Z","timestamp":1784477063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507452-anti-tumor-necrosis-factor-therapy-in-inflammatory-bowel-disease-effectiveness-and-challenges-in-a-moroccan-tertiary-care-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.112958","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,19]]}}}